Hims & Hers Health (NYSE:HIMS) Price Target Lowered to $6.00 at Citigroup

Hims & Hers Health (NYSE:HIMSGet Rating) had its target price lowered by Citigroup from $9.00 to $6.00 in a research note issued to investors on Tuesday morning, The Fly reports.

Several other research firms have also recently commented on HIMS. Zacks Investment Research cut Hims & Hers Health from a hold rating to a strong sell rating in a research report on Tuesday, April 26th. Guggenheim started coverage on Hims & Hers Health in a research report on Wednesday, April 13th. They issued a buy rating and a $10.00 target price on the stock. Deutsche Bank Aktiengesellschaft started coverage on Hims & Hers Health in a research report on Thursday, March 10th. They issued a hold rating and a $7.00 target price on the stock. Finally, Piper Sandler dropped their target price on Hims & Hers Health from $12.00 to $8.00 in a research report on Wednesday, February 23rd. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of Buy and a consensus target price of $10.56.

Hims & Hers Health stock opened at $3.45 on Tuesday. Hims & Hers Health has a one year low of $2.72 and a one year high of $15.55. The stock has a market capitalization of $707.50 million, a PE ratio of -9.58 and a beta of 0.38. The business’s fifty day moving average is $4.67 and its 200 day moving average is $5.52.

Hims & Hers Health (NYSE:HIMSGet Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). Hims & Hers Health had a negative return on equity of 22.41% and a negative net margin of 22.60%. The company had revenue of $101.30 million for the quarter, compared to analysts’ expectations of $90.99 million. During the same period last year, the firm posted ($0.14) earnings per share. Hims & Hers Health’s revenue was up 93.7% compared to the same quarter last year. As a group, research analysts anticipate that Hims & Hers Health will post -0.28 earnings per share for the current fiscal year.

In related news, Director Patrick Harrison Carroll sold 86,820 shares of Hims & Hers Health stock in a transaction that occurred on Monday, February 28th. The stock was sold at an average price of $5.17, for a total transaction of $448,859.40. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Lynne Chou O’keefe sold 10,044 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, March 17th. The shares were sold at an average price of $4.50, for a total value of $45,198.00. The disclosure for this sale can be found here. 43.70% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HIMS. Morgan Stanley purchased a new position in Hims & Hers Health during the 1st quarter valued at approximately $165,000. Wells Fargo & Company MN grew its holdings in Hims & Hers Health by 45.4% during the 2nd quarter. Wells Fargo & Company MN now owns 8,921 shares of the company’s stock valued at $97,000 after buying an additional 2,786 shares in the last quarter. Advisor Group Holdings Inc. grew its holdings in Hims & Hers Health by 77.4% during the 3rd quarter. Advisor Group Holdings Inc. now owns 6,926 shares of the company’s stock valued at $51,000 after buying an additional 3,021 shares in the last quarter. Ieq Capital LLC purchased a new position in Hims & Hers Health during the 3rd quarter valued at approximately $467,000. Finally, BlackRock Inc. grew its holdings in Hims & Hers Health by 63.2% during the 3rd quarter. BlackRock Inc. now owns 2,151,909 shares of the company’s stock valued at $16,225,000 after buying an additional 833,033 shares in the last quarter. Institutional investors and hedge funds own 57.22% of the company’s stock.

Hims & Hers Health Company Profile (Get Rating)

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.

Recommended Stories

The Fly logo

Analyst Recommendations for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.